Molecular targets of psychedelic‐induced plasticity

Psychedelic research across different disciplines and biological levels is growing at a remarkably fast pace. In the prospect of a psychedelic drug becoming again an approved treatment, much of these efforts have been oriented toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic interest. Considering the central role of the serotonin 5‐HT2A receptor in the distinct effects of psychedelics in human psyche, neuropharmacology sits at the center of this debate and exploratory continuum. Here we discuss some of the most recent findings in human studies and contextualize them considering previous preclinical models studying phenomena related to synaptic plasticity. A special emphasis is placed on knowledge gaps, challenges, and limitations to evaluate the underpinnings of psychedelics’ potential antidepressant action.

[1]  Lynette B Naler,et al.  Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice , 2021, Cell reports.

[2]  D. Nutt,et al.  Trial of Psilocybin versus Escitalopram for Depression. , 2021, The New England journal of medicine.

[3]  S. Thompson,et al.  Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice , 2021, Proceedings of the National Academy of Sciences.

[4]  Pasha A Davoudian,et al.  Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo , 2021, Neuron.

[5]  R. Carhart-Harris,et al.  Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing , 2021, Scientific Reports.

[6]  A. Tobeña,et al.  Increased thin-spine density in frontal cortex pyramidal neurons in a genetic rat model of schizophrenia-relevant features , 2021, European Neuropsychopharmacology.

[7]  J. González-Maeso,et al.  Psychedelic-like Properties of Quipazine and Its Structural Analogues in Mice. , 2021, ACS chemical neuroscience.

[8]  D. De Gregorio,et al.  Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms , 2021, Pharmacological Reviews.

[9]  B. Roth,et al.  International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function , 2020, Pharmacological Reviews.

[10]  D. Nutt,et al.  Self-blinding citizen science to explore psychedelic microdosing , 2020, eLife.

[11]  Brandon M. Brown,et al.  A Non-Hallucinogenic Psychedelic Analog with Therapeutic Potential , 2020, Nature.

[12]  Matthew W. Johnson,et al.  Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder , 2020, JAMA psychiatry.

[13]  H. Leite-Almeida,et al.  Chronic pain impact on rodents’ behavioral repertoire , 2020, Neuroscience & Biobehavioral Reviews.

[14]  C. Nichols,et al.  Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression. , 2020, ACS chemical neuroscience.

[15]  D. E. Olson,et al.  Psychedelic Microdosing: Prevalence and Subjective Effects , 2020, Journal of psychoactive drugs.

[16]  Javier González-Maeso,et al.  Automated quantification of head-twitch response in mice via ear tag reporter coupled with biphasic detection , 2020, Journal of Neuroscience Methods.

[17]  J. Wallach,et al.  Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species , 2020, Neuropharmacology.

[18]  Hiba Z. Vohra,et al.  Fully automated head-twitch detection system for the study of 5-HT2A receptor pharmacology in vivo , 2019, Scientific Reports.

[19]  L. Pani,et al.  Microdosing psychedelics: More questions than answers? An overview and suggestions for future research , 2019, Journal of psychopharmacology.

[20]  Lynette B Naler,et al.  MOWChIP-seq for low-input and multiplexed profiling of genome-wide histone modifications , 2019, Nature Protocols.

[21]  D. E. Olson,et al.  Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents , 2019, ACS chemical neuroscience.

[22]  I. Maze,et al.  Chromatin regulation in complex brain disorders , 2019, Current Opinion in Behavioral Sciences.

[23]  J. Gosden,et al.  Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans , 2018, Neuropharmacology.

[24]  Matthew W. Johnson,et al.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act , 2018, Neuropharmacology.

[25]  Dhwanil A. Dalwadi,et al.  Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs , 2018, Pharmacological Reviews.

[26]  D. E. Olson,et al.  Psychedelics Promote Structural and Functional Neural Plasticity , 2018, Cell reports.

[27]  D. E. Olson,et al.  Effects of N, N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression. , 2018, ACS chemical neuroscience.

[28]  G. Marek,et al.  Metabotropic Glutamate2 Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice , 2018, Front. Pharmacol..

[29]  D. Nutt,et al.  Psychiatry & the psychedelic drugs. Past, present & future , 2017, Neuropharmacology.

[30]  Evan J. Kyzar,et al.  Psychedelic Drugs in Biomedicine. , 2017, Trends in pharmacological sciences.

[31]  Matthew W. Johnson,et al.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial , 2016, Journal of psychopharmacology.

[32]  R. McLaughlin,et al.  The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. , 2016, Pharmacological research.

[33]  M. Liechti,et al.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens , 2016, European Neuropsychopharmacology.

[34]  Dhwanil A. Dalwadi,et al.  Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. , 2016, Pharmacological research.

[35]  James Rucker,et al.  Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. , 2016, The lancet. Psychiatry.

[36]  F. Vollenweider,et al.  Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects , 2015, Biological Psychiatry.

[37]  Chang Lu,et al.  A microfluidic device for epigenomic profiling using 100 cells , 2015, Nature Methods.

[38]  J. Krystal,et al.  Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. , 2015, Annual review of medicine.

[39]  R. Strassman,et al.  Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study , 2015, Journal of psychopharmacology.

[40]  W. Fantegrossi,et al.  Tolerance and Cross-Tolerance to Head Twitch Behavior Elicited by Phenethylamine- and Tryptamine-Derived Hallucinogens in Mice , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[41]  Åsa K. Björklund,et al.  Full-length RNA-seq from single cells using Smart-seq2 , 2014, Nature Protocols.

[42]  Javier González-Maeso,et al.  The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties , 2013, Neuropsychopharmacology.

[43]  Åsa K. Björklund,et al.  Smart-seq2 for sensitive full-length transcriptome profiling in single cells , 2013, Nature Methods.

[44]  E. Nestler,et al.  The brain reward circuitry in mood disorders , 2013, Nature Reviews Neuroscience.

[45]  A. Koleske.  Molecular mechanisms of dendrite stability , 2013, Nature Reviews Neuroscience.

[46]  T. S. Krebs,et al.  Over 30 million psychedelic users in the United States , 2013, F1000Research.

[47]  M. Geyer,et al.  Characterization of the head-twitch response induced by hallucinogens in mice , 2013, Psychopharmacology.

[48]  L. Tsai,et al.  Histone acetylation: molecular mnemonics on the chromatin , 2013, Nature Reviews Neuroscience.

[49]  J. González-Maeso,et al.  Animal models of serotonergic psychedelics. , 2013, ACS chemical neuroscience.

[50]  G. Aghajanian,et al.  Synaptic Dysfunction in Depression: Potential Therapeutic Targets , 2012, Science.

[51]  D. Morgan,et al.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. , 2012, Drug testing and analysis.

[52]  T. S. Krebs,et al.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.

[53]  E. Palazidou.  The neurobiology of depression. , 2012, British medical bulletin.

[54]  L. Bohn,et al.  Serotonin, But Not N-Methyltryptamines, Activates the Serotonin 2A Receptor Via a β-Arrestin2/Src/Akt Signaling Complex In Vivo , 2010, The Journal of Neuroscience.

[55]  Michael Kometer,et al.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.

[56]  D. Airey,et al.  The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen , 2010, Psychopharmacology.

[57]  Paul Greengard,et al.  Essential Role of the Histone Methyltransferase G9a in Cocaine-Induced Plasticity , 2010, Science.

[58]  Ryan T. Strachan,et al.  Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling , 2009, Proceedings of the National Academy of Sciences.

[59]  T. Insel,et al.  The STAR*D trial: revealing the need for better treatments. , 2009, Psychiatric services.

[60]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[61]  Matthew W. Johnson,et al.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later , 2008, Journal of psychopharmacology.

[62]  N. Spruston.  Pyramidal neurons: dendritic structure and synaptic integration , 2008, Nature Reviews Neuroscience.

[63]  L. Bohn,et al.  Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo , 2008, Proceedings of the National Academy of Sciences.

[64]  G. Aghajanian,et al.  Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: Role of corticosterone-mediated apical dendritic atrophy , 2008, Proceedings of the National Academy of Sciences.

[65]  D. Marona-Lewicka,et al.  Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action , 2007, Pharmacology Biochemistry and Behavior.

[66]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[67]  R. Thisted,et al.  Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis , 2005, Psychopharmacology.

[68]  J. Halpern.  Hallucinogens and dissociative agents naturally growing in the United States. , 2004, Pharmacology & therapeutics.

[69]  S. Sealfon,et al.  Transcriptome Fingerprints Distinguish Hallucinogenic and Nonhallucinogenic 5-Hydroxytryptamine 2A Receptor Agonist Effects in Mouse Somatosensory Cortex , 2003, The Journal of Neuroscience.

[70]  N. Darmani,et al.  Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover , 2003, Pharmacology Biochemistry and Behavior.

[71]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[72]  C. Nichols,et al.  Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration. , 2003, Brain research. Molecular brain research.

[73]  S. Sealfon,et al.  Validated Genomic Approach to Study Differentially Expressed Genes in Complex Tissues , 2002, Neurochemical Research.

[74]  C. Nichols,et al.  A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain , 2002, Neuropsychopharmacology.

[75]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[76]  M. Geyer,et al.  Increased Exploratory Activity and Altered Response to LSD in Mice Lacking the 5-HT5A Receptor , 1999, Neuron.

[77]  J. Halpern,et al.  Do hallucinogens cause residual neuropsychological toxicity? , 1999, Drug and alcohol dependence.

[78]  Andreas Bäbler,et al.  Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action , 1998, Neuroreport.

[79]  Kinzo Matsumoto,et al.  α2-Adrenoceptor Antagonists Reverse the 5-HT2 Receptor Antagonist Suppression of Head-Twitch Behavior in Mice , 1997, Pharmacology Biochemistry and Behavior.

[80]  H. D. Abraham,et al.  The Psychopharmacology of Hallucinogens , 1996, Neuropsychopharmacology.

[81]  R. Glennon,et al.  Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions , 1990, Pharmacology Biochemistry and Behavior.

[82]  R. Glennon,et al.  Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. , 1984, Life sciences.

[83]  D. Woolley.  PRODUCTION OF ABNORMAL (PSYCHOTIC?) BEHAVIOR IN MICE WITH LYSERGIC ACID DIETHYLAMIDE, AND ITS PARTIAL PREVENTION WITH CHOLINERGIC DRUGS AND SEROTONIN. , 1955, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. González-Maeso,et al.  Hallucinogens: Circuits, Behavior, and Translational Models , 2016 .

[85]  osé Morenoa,et al.  etabotropic glutamate mGlu 2 receptor is necessary for the pharmacological nd behavioral effects induced by hallucinogenic 5-HT 2 A receptor agonists , 2011 .

[86]  K. Murnane,et al.  The behavioral pharmacology of hallucinogens. , 2008, Biochemical pharmacology.

[87]  S. Sealfon,et al.  Monitoring G-protein-coupled receptor signaling with DNA microarrays and real-time polymerase chain reaction. , 2002, Methods in enzymology.

[88]  D. Pandya,et al.  Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice , 2000, Journal of Neural Transmission.

[89]  R. Glennon.  Classical hallucinogens: an introductory overview. , 1994, NIDA research monograph.

[90]  S. Kobayashi,et al.  [Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants]. , 1989, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[91]  A. Hofmann.  How LSD originated. , 1979, Journal of psychedelic drugs.